Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma.
BACKGROUND
Inhalation of a single dose of the long-acting beta 2-adrenoceptor agonist salmeterol protects against methacholine-induced airway obstruction and other bronchoconstricting stimuli for at least 12 hours. Hypothetically, twice daily dosing of salmeterol may result in continuous protection.


OBJECTIVE
This study was designed to investigate the protective effect of a single dose of salmeterol and of continuous twice daily treatment on airway responsiveness to methacholine.


METHODS
In a double- blind, parallel study, salmeterol 50 micrograms twice daily was compared with salbutamol 200 micrograms twice daily. Thirty children with mild asthma, who had little or no bronchial obstruction and were hyperresponsive to methacholine (PD20 < or = 150 micro g) were allocated to receive either salmeterol or salbutamol. Airway responsiveness was measured before study entry, 12 hours after a single dose of drug was given, and monthly during 4 months of daily treatment. Measurements were always performed at the same time of the day, 12 hours after the last dose of medication was administered.


RESULTS
No significant differences in FEV 1 were found between treatments at any time point. PD20 significantly increased after the first dose of salmeterol was given (geometric mean, 100 micro g). Geometric mean PD20 values were significantly better during salmeterol treatment than during salbutamol treatment, 52 and 25 micro g, respectively (p = 0.005).


CONCLUSIONS
The protection provided by salmeterol during maintenance treatment was less than that provided after the first dose (p <0.001). However, protection did not diminish during the 4-month treatment period and remained significant compared with baseline (p = 0.003).
Verberne
A A
AA
Department of Pediatrics, Erasmus University, University Hospital, Rotterdam, The Netherlands.
Hop
W C
WC
Creyghton
F B
FB
van Rooij
R W
RW
van den Berg
M
M
de Jongste
J C
JC
Kerrebijn
K F
KF
D000293:Adolescent; D000403:Airway Resistance / Q000187:drug effects; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology*; D016084:Bronchoconstriction / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D000068299:Salmeterol Xinafoate
D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol